ELMD Stock Analysis: Electromed | NYSE MKT
Medical Devices | NYSE MKT, USA | Market Cap: 378m USD | 12M Return: 128.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.39M
EPS Trend: 98.8%
Qual. Beats: 2
Rev. Trend: 99.9%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Seasonality 11.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Electromed, Inc. (ELMD) is a medical technology company specializing in high-frequency chest wall oscillation (HFCWO) therapy. The firm designs and manufactures the SmartVest system, a device used to clear excess mucus from the lungs of patients with chronic respiratory conditions such as bronchiectasis and cystic fibrosis. Its product ecosystem includes the SmartVest SQL and Clearway systems, alongside SmartVest Connect, a wireless platform for remote patient monitoring and physician data integration.
The company operates within the specialized pulmonary care segment of the healthcare equipment industry, utilizing a direct-to-patient and provider-based sales model. HFCWO technology serves as a critical maintenance therapy for neuromuscular and obstructive lung diseases, often reducing hospital readmission rates for chronic patients. For deeper insights into these industry trends, readers may find further analysis on ValueRay beneficial.
Headquartered in Minnesota, Electromed markets its proprietary single-hose pulse generator technology to both acute care facilities and home-care settings. The business model relies on a combination of capital equipment sales and recurring revenue from single-patient-use garments and accessories.
- SmartVest revenue growth driven by increased bronchiectasis diagnosis and physician referrals
- Gross margin expansion through manufacturing efficiencies and direct-to-patient sales model
- Sales force expansion accelerates market share gains in HFCWO therapy segment
- Medicare and private insurance reimbursement policy changes impact patient access and pricing
| Net Income: 10.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA -5.57 > 1.0 |
| NWC/Revenue: 55.75% < 20% (prev 58.08%; Δ -2.33% < -1%) |
| CFO/TA 0.18 > 3% & CFO 10.5m > Net Income 10.1m |
| Net Debt (-16.8m) to EBITDA (14.8m): -1.14 < 3 |
| Current Ratio: 4.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (8.65m) vs 12m ago -3.57% < -2% |
| Gross Margin: 78.44% > 18% (prev 77.55%; Δ 0.89% > 0.5%) |
| Asset Turnover: 128.2% > 50% (prev 117.1%; Δ 11.08% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.67 (Total Current Assets 50.2m - Total Current Liabilities 10.2m) / Total Assets 59.5m |
| B: 0.42 (Retained Earnings 25.1m / Total Assets 59.5m) |
| C: 0.24 (EBIT TTM 13.6m / Avg Total Assets 56.0m) |
| D: 4.77 (Book Value of Equity 49.2m / Total Liabilities 10.3m) |
| Altman-Z'' = 12.43 = AAA |
| DSRI: 0.95 (Receivables 28.3m/25.5m, Revenue 71.8m/61.4m) |
| GMI: 0.99 (GM 77.55% / 78.44%) |
| AQI: 1.30 (AQ_t 0.07 / AQ_t-1 0.05) |
| SGI: 1.17 (Revenue 71.8m / 61.4m) |
| TATA: -0.01 (NI 10.1m - CFO 10.5m) / TA 59.5m) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 45.65 with a total of 579,355 shares traded. Over the past week, the price has changed by +0.48%, over one month by +22.78%, over three months by +89.26% and over the past year by +128.14%.
Current recommended Stop Loss: 43.10 (which is 5.6% or 1.3 ATR below the current price).
Electromed has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy ELMD.
- StrongBuy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 40.3 | -11.7% |
P/E Trailing = 39.0598
P/E Forward = 20.2429
P/S = 5.2737
P/B = 7.6507
P/EG = 0.35
Revenue TTM = 71.8m USD
EBIT TTM = 13.6m USD
EBITDA TTM = 14.8m USD
Long Term Debt = unknown (none)
Short Term Debt = 73.0k USD (from shortTermDebt, last fiscal year)
Debt = 198k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -16.8m USD (calculated: Debt 198k - CCE 17.0m)
Enterprise Value = 361.6m USD (378.4m + Debt 198k - CCE 17.0m)
Interest Coverage Ratio = unknown (Ebit TTM 13.6m / Interest Expense TTM 0.0)
EV/FCF = 35.36x (Enterprise Value 361.6m / FCF TTM 10.2m)
FCF Yield = 2.83% (FCF TTM 10.2m / Enterprise Value 361.6m)
FCF Margin = 14.25% (FCF TTM 10.2m / Revenue TTM 71.8m)
Net Margin = 14.08% (Net Income TTM 10.1m / Revenue TTM 71.8m)
Gross Margin = 78.44% ((Revenue TTM 71.8m - Cost of Revenue TTM 15.5m) / Revenue TTM)
Gross Margin QoQ = 78.83% (prev 78.42%)
Tobins Q-Ratio = 6.08 (Enterprise Value 361.6m / Total Assets 59.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 198k)
Taxrate = 25.56% (3.47m / 13.6m)
NOPAT = 10.1m (EBIT 13.6m * (1 - 25.56%))
Current Ratio = 4.91 (Total Current Assets 50.2m / Total Current Liabilities 10.2m)
Debt / Equity = 0.00 (Debt 198k / totalStockholderEquity, last quarter 49.2m)
Debt / EBITDA = -1.14 (Net Debt -16.8m / EBITDA 14.8m)
Debt / FCF = -1.64 (Net Debt -16.8m / FCF TTM 10.2m)
Total Stockholder Equity = 45.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.05% (Net Income 10.1m / Total Assets 59.5m)
RoE = 22.14% (Net Income TTM 10.1m / Total Stockholder Equity 45.6m)
RoCE = 27.56% (EBIT 13.6m / Capital Employed (Total Assets 59.5m - Current Liab 10.2m))
RoIC = 22.09% (NOPAT 10.1m / Invested Capital 45.7m)
WACC = 7.62% (E(378.4m)/V(378.6m) * Re(7.62%) + D(198k)/V(378.6m) * Rd(0.0%) * (1-Tc(0.26)))
Discount Rate = 7.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -51.11 | Cagr: -0.77%
[DCF] Terminal Value 73.22% ; FCFF base≈10.9m ; Y1≈9.63m ; Y5≈7.88m
[DCF] Fair Price = 17.28 (EV 126.3m - Net Debt -16.8m = Equity 143.0m / Shares 8.28m; r=8.35% [WACC [floored]]; 5y FCF grow -14.36% → 2.50% )
EPS Correlation: 98.82 | EPS CAGR: 53.84% | SUE: 3.08 | # QB: 2
Revenue Correlation: 99.93 | Revenue CAGR: 15.59% | SUE: 1.83 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.29 | Chg30d=-1.14% | Revisions=-17% | Analysts=3
EPS current Year (2026-06-30): EPS=1.22 | Chg30d=+10.61% | Revisions=+25% | GrowthEPS=+43.1% | GrowthRev=+15.0%
EPS next Year (2027-06-30): EPS=1.48 | Chg30d=+12.12% | Revisions=+25% | GrowthEPS=+21.6% | GrowthRev=+13.6%
[Analyst] Revisions Ratio: +12% (up=3, down=2)